Dear Valued Provider,

If you are a healthcare partner who orders Veklury (remdesivir) for outpatient use, we ask for your participation in improving access to this medication for providers and their patients. The U.S. Department of Health and Human Services (HHS) aims to increase public awareness of where Veklury for outpatient use is available, information we currently make available for other COVID-19 medications. This initiative will allow visibility of Veklury outpatient infusion sites on the HHS COVID-19 Therapeutics Locator to assist in matching patients at high risk of severe COVID-19 to the medications that can prevent disease progression.

Any infusion site opting into this program will be featured on the COVID-19 Therapeutic Locator as an outpatient Veklury provider. The infusion site location information you provide will be the only information visible on the locator. Your infusion site can opt out of being on the locator at any time.

There is minimal engagement from you required; all that is needed is location information and agreement to participate. Your decision to participate can be reversed at any time. Participation does not constitute an agreement to share any other data with HHS. Please follow the link for more information and contact HHS at COVID19.Therapeutics@hhs.gov if you have any questions.

Please go to Provider Opt-In for ASPR Therapeutics Public Locator to opt into the initiative.

Regards,

HHS Coordination Operations and Response Element (H-CORE)
Administration for Strategic Preparedness and Response
U.S. Department of Health and Human Services

Disclaimer:
Reference on this website to any specific commercial product, process, service, manufacturer, or company is not an endorsement or recommendation by the U.S. Government or the U.S. Department of Health and Human Services (HHS).